Submitted Projects:

Project MIN102 developed a non-invasive device to deliver low-frequency ultrasound (LOTUS) to the kidneys, lungs, and other organs. LOTUS increases local nitric oxide, which acts to both kill the virus and protect the organ. The product has completed initial clinical testing to prevent contrast-induced kidney injury in the cath lab. We have received Breakthrough Device Designation from FDA. We aim to test the same device to prevent kidney injury due to COVID.

The project is led by Professor Francesca Cordeiro and Mr David Trevor commercialising DARC technology.
DARC technology uses a fluorescently labelled protein to identify stressed, sick and dying nerve cells which can be non-invasively imaged. Combined with a proprietary AI based algorithm, the no. and pattern of DARC spots enables the clinician to identify glaucoma patients 10 years ahead of current standard of care.
If you have a compound for glaucoma or AMD, including gene therapy or you are about to invest in such a company, we can de-risk your clinical development program & investment decision in 2-3 months instead of 2-3 years.

The project is committed to solving the huge clinical problem of heart failure rehospitalization. The company uses remote monitoring and AI algorithms to provide doctors and patients with the best diagnostic basis and medication control, effectively reducing the risk of heart failure patients with relapse and greatly reducing the frequency of hospitalization.